Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Improved Survival in BRAF-Mutated Melanoma With Trametinib | |
|
| |
Melanoma is a skin cancer that arises from pigment
cells called melanocytes. In the under
40-years population, melanoma is the second-most common cancer with 160,000
newly diagnosed cases and 48,000 related deaths every year. Nearly 50% advanced melanoma patients have
mutations in B-RAF (BRAF), an enzyme which modulates tumour cell growth.
Two mutations, V600E and V600K constitute 95% of observed BRAF mutations
Treatment with vemurafenib and ipilimumab enhance survival in BRAF-mutated
melanoma patients.
A clinical trial was sponsored by GlaxoSmithKline to evaluate the efficacy of trametinib on tumour progression and disease stabilization in melanoma patients. Patients with significant heart, lung or eye disease were excluded. The enrolled patients had un-resectable stage IIIC/IV cutaneous melanoma with V600E or V600K BRAF mutations.
Patients were randomly assigned to receive trametinib (2 mg/day) or intravenous chemotherapy (1000mg dacarbazine or 175mg paclitaxel per square meter) every 3 weeks. Progression-free survival was the primary end point, and overall survival, response rate, response duration and safety were secondary end points. Tumour assessments were conducted at weeks 0, 6, 12, 21, and 30 and quarterly thereafter.
The average progression-free survival was 4.8 months and 1.5 months in the trametinib and chemotherapy groups respectively (P<0.001). After 6 months, overall survival was 81% and 67% in the trametinib and chemotherapy groups respectively (P=0.01). The response rates, complete or partial response, were 22% and 8% in the trametinib and chemotherapy groups respectively (P=0.01). Both progression-free and overall survival was significantly longer in the trametinib group than in the chemotherapy group.
Progression-free survival did not substantially improve in patients with V600K mutation or ≥65 years.
Adverse events (AEs) were reported in over 15% patients who received at least one dose of study drug. Frequent AEs in trametinib group were rash, diarrhea, peripheral edema, fatigue, and acne-like eruptions, which were controlled by dose reduction and interruption. Reduced heart function was seen in 7% patients. Ocular events (often grade 1-2) occurred in 9% patients, while two patients had severe grade 3 cardiac-related events that led to termination of study drug treatment. AEs led to dose interruptions and reductions in 35% and 27% trametinib-treated patients respectively.
Chemotherapy-induced AEs included fatigue, nausea, constipation, vomiting, and alopecia with dose interruptions and reductions in 22% and 10% patients respectively. Skin cancers of the squamous-cell carcinoma type, previously reported in 18-26% of vemurafenib-treated patients, were absent in trametinib-treated population.
Thus trametinib, as compared with chemotherapy, improved progression-free and overall survival in metastatic melanoma patients with a BRAF V600E or V600K mutation.
Reference:Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma; Keith Flaherty et al; NEJM 2012
Source-Medindia
| |
|
|
 Comment & Contribute
|
Related Links
Fresh Approaches Possibly Prevent Certain Side Effects in BRAF Mutation-positive Melanoma
Results of preclinical studies in a skin cancer model expressed next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors ...
Vemurafenib Improves Survival in Advanced Malignant Melanoma
A new drug, vemurafenib, has recently been approved by the European Union for use in patients with advanced malignant melanoma with BRAF ...
New Promising Treatments Against Skin Cancer
Research shows new promising treatments against advanced melanoma. The agents, known as Dabrafenib and Trametinib, are being ...
Drug for Melanoma Shows Promise in Early Trial
An experimental drug for melanoma has successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international ...
Health Watch News
Women With Low BMI are More Prone to Endometriosis
Women who have a slim body are at a greater risk of developing endometriosis than women who are obese, suggests a recent study published in the ...
Eat Small Breakfast and Lose Weight Quickly!
Recently the scientists have contested the famous adage, "Eat breakfast like a king, lunch like a prince and dinner like a pauper." ...
Micronutrient Enriched Wheat Steamed Bread is Beneficial for Diabetes Patients
Steamed bread made from a new purple grain wheat variety developed by Chinese scientists may help lower blood sugar, according to a study ...
Stroke Survivors Need Emotional Support
Stroke is a condition characterized by death of brain cells due to inadequate supply of oxygen to brain cells. It can be of two types-hemorrhagic ...
Red Hair Pigment May Increase Risk of Melanoma, Skin Cancer
Fair skin is associated with increased risk of skin cancer. However, recent animal studies reveal that factors other than UV radiations are ...
Depression can be Treated by Deep Brain Stimulation
Deep Brain Stimulation may be used to treat depression, reveal new studies. Deep Brain Stimulation is a technique in which a ...
- Health News Index
- News Quick Links
 |
Melanoma
Complete Medindia Resources
|
| News Categories: |
| » | Health Campaigners Hail Brave Angelina Jolie's Mastectomy Revelation |
| » | Angelina Jolie's Breast Removal Surgery Boosts Cancer Awareness, Experts Advise Caution |
| » | Shakira Having Sleepless Nights During Pregnancy |
| » | Belgian Nobel Laureate Christian De Duve Dies |
| » | Sherri Shepherd Owes Her Life to Diabetes |
| More Celebrity News | |
|
Ask an Expert
